SAN DIEGO, Nov. 30 Amylin Pharmaceuticals, Inc.(Nasdaq: AMLN) will be presenting at the Nasdaq 20th Investor Program inLondon on Thursday, December 6, 2007 at 7:15 a.m. PT / 3:15 p.m. GMT localtime in the UK. Berthold Lensker, Ph.D., Executive Director of EuropeanOperations, will be providing a corporate overview of Amylin Pharmaceuticals.
The live presentation will be webcast, and a recording will be madeavailable following the event. The webcast and recording will be accessiblethrough Amylin's corporate website, located at http://www.amylin.com. Toaccess the live webcast, please log on to Amylin's site approximately fifteenminutes prior to the presentation to register and download any necessary audiosoftware.
More information about the Nasdaq 20th Investor Program is available at:http://december.nasdaqconference.com/info.asp.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company committed toimproving lives through the discovery, development and commercialization ofinnovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection andBYETTA(R) (exenatide) injection. Amylin's research and development activitiesleverage the company's expertise in metabolism to develop potential therapiesto treat diabetes and obesity. Amylin is located in San Diego, Californiawith over 1,800 employees nationwide. Further information on AmylinPharmaceuticals is available at http://www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.